Polyclonal B cell activation is an early feature of autoimmune disease in humans and mice with systemic lupus erythematosus. The contribution of polyclonal activation to the progression of autoimmunity is unclear, however, since it precedes the development of end-organ damage by months or years. To examine this issue, 109 autoimmune-prone (NZB X NZW)Fj X NZB backcross mice were hemi-splenectomized at 10 wk and the number and antigenic specificity of their Ig-secreting B cells quantitated by ELISA spot assay. Of the 61 mice that had polyclonally increased numbers of Ig-secreting cells/spleen, 31 died by 6 mo. In contrast, 0/48 backcross mice with normal numbers of Ig-secreting B cells at 10 wk died over the same period (P < 0.001). Polyclonally activated mice also developed proteinuria earlier and more frequently than littermates with normal numbers of Ig-secreting cells (P < 0.001).
Introduction
(NZB X NZW)Fj mice spontaneously develop an autoimmune syndrome that resembles human systemic lupus erythematosus (SLE). Their disease is characterized by the production of IgG autoantibodies reactive with a variety of self antigens at 5-9 mo followed by immune complex-mediated glomerulonephritis and death (1) (2) (3) (4) (5) (6) (7) . NZB mice develop an autoimmune disease which features hemolytic anemia and the increased production of IgM autoantibodies (8, 9) . NZW mice are less autoimmune-prone but contribute genes critical to the development of lupus nephritis in (NZB X NZW)Fj animals (10, 11) .
Two processes, polyclonal B cell activation and autoantigen-driven immune stimulation, are thought to contribute to the production of autoantibodies in SLE (12) (13) (14) (15) (16) . There is considerable uncertainty, however, concerning the relative importance of these two processes to disease pathogenesis. A role for autoantigen in the perpetuation of autoimmunity is supported by evidence showing that (a) heightened responses to specific autoantigens are pathognomonic of active disease (such as the anti-DNA response in (NZB X NZW)Fj mice and humans with lupus [4, 7, 17, 18] ); (b) certain autoantigens are able to induce immune responses against themselves (19) (20) (21) ; (c) autoantibody-secreting B cells switch from IgM to IgG production over the course of disease (18, 20) ; (d) autoantibody affinity increases over time in a pattern reminiscent of conventional antigen-driven immune responses (4, 5) ; and (e) autoantibody-secreting lymphocytes express clonally related IgVh region genes, consistent with a process of antigen-driven B cell selection and expansion (14, 22 ). Yet there is also evidence which links the development of polyclonal B cell activation with lupus. For example, the number of B cells secreting non-autoantibodies as well as autoantibodies is significantly increased in mice and humans with SLE as is the responsiveness of lupus B cells to activation by T cell-derived lymphokines (13, (23) (24) (25) (26) (27) (28) (29) .
It has been difficult to assess the contribution of polyclonal activation to the pathogenesis of SLE due to the confounding influence of autoantigen-specific immune stimulation. In all autoimmune strains studied to date, both of these processes have been detected (13, 21, 23) , making it impossible to independently assess the contribution of polyclonal activation to disease progression. The present study was designed to circumvent this problem by studying (NZB X NZW)Fj X NZB backcross mice. These backcross mice inherit a complex assortment of autoimmunity associated genes (approximately six from the NZB parent [6, 10, 11, [30] [31] [32] and at least two of NZW origin [10, 11] ) and as a result show considerable variation in their autoimmune phenotype including a dissociation between polyclonal activation and autoantigen-specific stimulation (10, 11, (33) (34) (35) .
In this report, the presence of polyclonal activation and autoantigen-specific immune stimulation were monitored as a function of disease progression in 109 backcross mice using a sensitive and specific ELISA spot assay (13, 36, 37) . Results indicate that polyclonal B cell activation precedes and predicts the development of immune-mediated glomerulonephritis. In older mice, active renal disease was associated with the preferential production of anti-DNA (but not anti-ovalbumin) antibodies. However in younger mice, increased anti-DNA production did not correlate with subsequent disease progression. These findings are consistent with a model in which autoantibody production in lupus is initiated by polyclonal activation and perpetuated by autoantigen-specific stimulation (21, 38 40) or glutaraldehyde-fixed bromelain-treated mouse red blood cells (41) , and then blocked with 1% BSA in PBS as previously described (13) . Serial dilutions of single cell suspensions, starting with 106 cells/well, were incubated on antigen-coated plates for 7 h at 370 in a 5% CO2 in air incubator as previously described (42 (36) . The dilution of cells producing spots/well was used to determine the total number of antibody-specific B cells/sample. The presence of BSA in the FCS used to conduct these assays completely inhibited the binding of BSA-specific antibodies to BSA-blocked plates, giving the assay a zero background. The sensitivity and specificity of this assay has been documented in antigen inhibition tests and in studies involving antigen-specific hybridoma cell lines (13, 36, 37 (Fig. 2) ; (b) the number of F1 B cells secreting antibodies reactive with each antigen in the panel increased > 14-fold between 10 wk and 8 mo, consistent with the effects of polyclonal activation (Fig. 3, top) ; and (c) reactivity against the autoantigens DNA and histone increased by 130-and 240-fold in these mice, consistent with specific immune responses against these autoantigens (Fig. 3, bottom) . mo did not distinguish between mice with and without glomerulonephritis (Fig. 5) . In contrast, mice with proteinuria had rlicnrunnrtiunnqtPlv inmrenqeA numherq nf T cell-, secreting TaM Polyclonal activation predicts the development of autoimmune disease in F, X NZB mice. A majority of adult F. mice develop an autoimmune-mediated glomerulonephritis that has been linked to the production of IgG autoantibodies reactive with DNA (7, 18) . Some F. X NZB backcross mice also develop renal disease although at a lower frequency than among Fl's (1 1, 35) . A detailed analysis ofB cell activation and disease progression was undertaken in backcross animals to identify the factor(s) associated with disease progression. A cohort of 109 F. X NZB female mice were hemi-splenectomized at 10 wk and examined by ELISA spot assay for (a) the presence of polyclonal B cell activation; (b) the presence of autoantigen-specific immune responses; and (c) the relation of (a) and (b) to the subsequent development of glomerulonephritis and death.
Backcross mice were considered to be polyclonally activated if the frequency of B cells secreting Ig in their spleens exceeded by > 2 SD the mean frequency of Ig-secreting B cells in NZW mice of the same age. Using this definition, polyclonal activation was detected in 56% of 10-wk-old F. X NZB animals (Fig. 2) . IgM rather than IgG was secreted by 93-98% of the activated B cells in mice of this age (data not shown).
In the group of animals with normal numbers of Ig-secreting B cells, 63% survived until 12 mo and none died from autoimmune disease within the first 6 mo of life (Fig. 4) . In contrast, nearly half of the mice with polyclonal activation died within 6 mo (P < 0.001, Chi squared analysis) and only 23% survived for 1 yr (P < 0.01). Mice with polyclonal activation also developed proteinuria more frequently and at an earlier age than littermates with normal numbers of Ig-secreting B cells (P < 0.001, Fig. 4) .
Anti-DNA and anti-ovalbumin production in 10-wk-old F, X NZB mice. 10-wk-old backcross mice with significantly in- (Fig. 5 ). The repertoires which had been expressed by these two groups at 10 wk were then compared. Mice with proteinuria as adults had normal anti-DNA repertoires but more than twice as many Ig-secreting B cells at 10 wk than did littermates that did not develop proteinuria (Fig. 6 ).
Discussion
Results from this work indicate that polyclonal B cell activation precedes and predicts the development of glomerulonephritis and premature death in lupus-prone (NZB X NZW)F1 X NZB mice. At 10 wk approximately one-half of backcross mice had significantly elevated numbers of Ig-secreting splenic (39) . While this approach was technically more difficult than conventional studies of serum Ig levels, it provided data on the state of B cell activation unobtainable by conventional serum studies. As we and others have shown (a) ELISA spot assays are -20 times more sensitive than serum ELISA assays (13, 36, 37) , and (b) the concentration of Ig in serum does not reflect the rate of Ig production or B cell stimulation alone but rather the balance between production and degradation. Since the rate of Ig catabolism increases as serum Ig levels rise (44) , the effect of polyclonal activation on antibody production can be underestimated in studies of serum Ig levels, a problem which is resolved by using the ELISA spot assay to measure B cell activation directly. Many laboratories have provided evidence that polyclonal activation contributes to autoantibody production in lupusprone mice (12, 13, 15, 23) . The present report is the first to link the presence of such activation to the progression of autoimmune disease. Yet polyclonal activation was not invari- (7, 18) . Consistent with these findings, we observed that glomerulonephritis in adult F. and backcross mice was associated with a preferential increase in anti-DNA secreting B cells (Fig.  5) . NZB/W mice have also been shown to have disproportionately heightened responses to histone, retroviral GP 70, and T cells surface antigens (10, 34, 35) . This set of findings suggests that multiple (auto)antigens may contribute to the autoantibody production characteristic of murine lupus. However, the observation that anti-DNA production in I0-wk-old backcross mice does not correlate with disease progression (Fig. 6) suggests that this autoantigen-dependent immune stimulation occurs primarily during the latter stages of disease.
In this study, B cell activation in backcross mice was monitored by ELISA spot analysis of Ig-secreting lymphocytes in 14% of the animals examined in this report to the polyclonally activated or normal groups. The actual number of animals assigned incorrectly is probably much lower, since (a) experimental variability was frequently less than 10%, and (b) any error in quantitating the number of Ig-secreting B cells would be equally likely to place an animal more firmly in the correct category rather than to change its category. When the data were reexamined to exclude mice with intermediate numbers of Ig-secreting B cells (which might have been incorrectly assigned) the correlation between polyclonal activation and disease progression persisted. For example, the group of mice with the highest 25% of Ig-secreting cells/spleen had a mortality rate of 87% by 12 mo whereas the group ofmice with the lowest 25% of Ig-secreting cells had a mortality rate of under 35% (P < 0.01).
Previous studies have shown that at least two independently segregating loci in NZW mice (one of which is associated with the MHC locus) and at least six genetic loci in NZB mice influence autoantibody production and/or disease (2, 10, 30, 31, (33) (34) (35) (45) (46) . Analyses of multiple autoimmune, normal, and recombinant inbred mouse strains have demonstrated further that the trait of polyclonal activation breeds true (13, 23) . The autoimmune phenotypes expressed by backcross mice may therefore reflect a complex interaction between multiple autoimmunity-associated genes. For example, while all NZB mice and no NZB mice developed polyclonal activation by 10 wk, 90% of F1 animals (which are heterozygous at all loci) and just over half of backcross mice (which inherit a mixture of homozygous NZB and heterozygous NZB/NZW genes) expressed significantly increased numbers of Ig-secreting B cells at that age. Additional backcross mice developed polyclonal activation as they grew older, so that by 12 mo nearly 90% of all animals had increased numbers of Ig-secreting B cells. Such complexity in the expression ofa trait is not easily attributed to a single gene. Similar complexity is seen in the development ofIgG hypergammaglobulinemia and glomerulonephritis. These traits are absent from most NZB and NZW parental mice, present in most Fj's, but show considerable variability in age of onset and severity in backcross animals (2, 11, 33) .
We recently postulated that murine lupus develops in two phases, the first being characterized by polyclonal B cell activation and the second by the (auto)antigen-driven expansion ofautoreactive B cells (13, 21, 38) . Results from this and other laboratories indicate that the autoantigen-specific phase of SLE serves to magnify and perpetuate the production ofpathogenic autoantibodies (such as those against DNA in (NZB X NZW)F1 mice and against Sm in MRL-/pr/lpr mice (4, 7, 19, 21) ). Findings in the present report emphasize the correlation which exists between polyclonal activation and the development of active disease. In this context, polyclonal activation might serve to (a) initiate the production ofthose autoantibodies that cause tissue damage and the release ofautoantigens; (b) increase the pool of self-reactive B cells available for later autoantigen-specific stimulation; (c) interfere with the development of self tolerance by stimulating B cells that would otherwise be deleted; or (d) disrupt the regulatory environment required for normal immune function (for example by interfering with the development of Id-anti-Id networks). These observations invite further study into the possibility that therapy during the early polyclonal phase of human and murine lupus might prevent or delay disease progression.
